Ticker,Title,Link
ARAV,Why 3M Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session,1/23/2024 8:37:35 PM
ARAV,Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session,1/18/2024 7:08:49 PM
ARAV,"Aravive, Inc. to Delist from The Nasdaq Stock Market",1/17/2024 10:09:41 PM
ARAV,Why Adial Pharmaceuticals Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session,10/20/2023 7:45:09 PM
ARAV,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday,10/18/2023 11:25:32 AM
ARAV,Why America's Car-Mart Are Trading Lower By 12%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session,9/5/2023 7:34:34 PM
ARAV,Why REX American Resources Are Trading Lower By 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session,8/30/2023 7:17:52 PM
ARAV,"Analyst Downgrades Aravive: Grapples With Trial Setback, Strategic Alternatives",8/22/2023 10:35:40 PM
ARAV,Crude Oil Rises 2.5%; Kellogg Posts Upbeat Earnings,8/3/2023 8:43:01 PM
ARAV,"Catalyst Watch: Amazon earnings, jobs report, and will Apple talk AI?",7/28/2023 6:00:40 PM
ARAV,"WW, HRTX and WAL are among pre market gainers",7/26/2023 12:28:03 PM
ARAV,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday,7/25/2023 11:31:01 AM
ARAV,The Latest Analyst Ratings for Aravive,7/21/2023 4:00:35 PM
ARAV,Why Icahn Enterprises Shares Are Trading Higher By 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session,7/10/2023 6:34:29 PM
ARAV,The Latest Analyst Ratings for Aravive,7/3/2023 7:02:53 PM
ARAV,3 Short-Squeeze Stocks Set for a Spectacular Gamma Squeeze Rally,6/16/2023 1:46:05 AM
ARAV,H.C. Wainwright Sticks to Its Buy Rating for Aravive (ARAV),6/5/2023 10:25:11 AM
ARAV,BTIG Keeps Their Buy Rating on Aravive (ARAV),6/2/2023 10:25:08 AM
ARAV,Analyst Expectations for Aravive's Future,5/25/2023 5:00:42 PM
ARAV,7 Short-Interest Stocks to Target for Explosive Gains,5/18/2023 8:37:15 PM
ARAV,H.C. Wainwright Sticks to Their Buy Rating for Aravive (ARAV),5/16/2023 2:25:15 PM
ARAV,Aravive (ARAV) Receives a Buy from EF Hutton,5/11/2023 12:27:24 PM
ARAV,"Aravive GAAP EPS of -$0.66 misses by $0.34, revenue of $1.49M beats by $1.07M",5/10/2023 9:23:02 PM
ARAV,7 Short-Squeeze Stocks That Are Driving Hedge Funds Crazy,4/16/2023 6:14:18 PM
ARAV,BTIG Keeps Their Buy Rating on Aravive (ARAV),4/3/2023 11:05:05 AM
ARAV,7 Short-Squeeze Stocks That Could Explode in April,3/30/2023 6:07:39 PM
ARAV,4 Analysts Have This to Say About Aravive,3/16/2023 3:00:54 PM
ARAV,"Analysts Are Bullish on These Healthcare Stocks: Aravive (ARAV), PainReform (PRFX)",3/15/2023 3:20:20 PM
ARAV,Aravive stock pops on FDA orphan drug status for batiraxcept to treat pancreatic cancer,3/1/2023 10:01:53 AM
ARAV,2 “Strong Buy” Penny Stocks With Multibagger Potential,2/23/2023 3:43:45 PM
ARAV,Aravive (ARAV) Receives a Buy from H.C. Wainwright,2/21/2023 11:15:06 AM
ARAV,"Analysts Offer Insights on Healthcare Companies: Oramed Pharm (ORMP), Aravive (ARAV) and Frequency Therapeutics (FREQ)",2/14/2023 12:30:47 PM
ARAV,"Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023",1/5/2023 4:01:20 PM
ARAV,"Analysts Are Bullish on Top Healthcare Stocks: Aravive (ARAV), Hookipa Pharma (HOOK)",1/4/2023 2:30:26 PM
ARAV,Aravive Announces Fast Track Designation Of Batiraxcept - Quick Facts ,11/29/2022 1:30:26 PM
ARAV,Aravive To Participate in Piper’s 34th Annual Healthcare Conference,11/21/2022 1:00:00 PM
ARAV,Aravive Regains Compliance with Nasdaq Minimum Bid Price Requirement,11/16/2022 1:00:00 PM
ARAV,H.C. Wainwright Sticks to Their Buy Rating for Aravive (ARAV),11/10/2022 3:15:14 PM
ARAV,Why Greenhill Shares Climbed Around 25%; Here Are 100 Biggest Movers From Yesterday,11/4/2022 9:41:55 AM
ARAV,Why Harsco Shares Surged Over 22%; Here Are 80 Biggest Movers From Yesterday,11/2/2022 10:07:53 AM
ARAV,MNSO and CLEU among mid-day movers,11/1/2022 5:40:03 PM
ARAV,Why Global Payments Shares Are Trading Lower By Around 8%? Here Are 41 Stocks Moving In Monday's Mid-Day Session,10/31/2022 5:21:44 PM
ARAV,Aravive Announces Approximately $41.5 Million Private Placement Financing,10/25/2022 1:30:00 PM
ARAV,"Analysts Offer Insights on Healthcare Companies: Aravive (ARAV), Keros Therapeutics (KROS) and Legend Biotech (LEGN)",10/12/2022 1:40:58 PM
ARAV,"Analysts’ Top Healthcare Picks: Aravive (ARAV), scPharmaceuticals (SCPH)",10/11/2022 10:31:08 AM
ARAV,Aravive Receives Third Development Milestone from 3D Medicines,10/10/2022 10:05:00 PM
ARAV,Aravive to Participate in the Cantor Fitzgerald Oncology & HemOnc Conference,9/26/2022 2:00:00 PM
ARAV,Why SOBR Safe Shares Surged Around 233%; Here Are 68 Biggest Movers From Yesterday,9/21/2022 9:04:38 AM
ARAV,"Why Virios Therapeutics Is Trading Lower By 75%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session",9/20/2022 6:41:49 PM
ARAV,Why Immunocore Shares Dipped 22%; Here Are 73 Biggest Movers From Friday,9/12/2022 9:23:41 AM
ARAV,"Why Zscaler Is Trading Higher By Around 19%, Here Are 44 Stocks Moving In Friday's Mid-Day Session",9/9/2022 6:23:18 PM
ARAV,Aravive to Participate in H.C. Wainwright 24th Annual Global Investment Conference,9/6/2022 10:05:00 PM
ARAV,Aravive Reports Second Quarter 2022 Financial Results and Provides Corporate Updates,8/11/2022 1:00:00 PM
ARAV,Aravive Appoints Dr. Robert B. Geller as Chief Medical Officer,7/5/2022 3:07:03 PM
ARAV,"Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022",6/3/2022 4:08:02 PM
ARAV,Aravive Presents Updated Clinical Data at ASCO Showing Continued Best-in-Class Potential of Batiraxcept in Advanced or Metastatic clear cell Renal Cell Carcinoma (ccRCC),5/26/2022 11:11:43 PM
ARAV,Aravive to Participate in H.C. Wainwright Global Investment Conference,5/17/2022 1:00:00 PM
ARAV,Aravive Reports First Quarter 2022 Financial Results and Provides Corporate Updates,5/12/2022 1:00:00 PM
ARAV,"Aravive to Host Key Opinion Leader Symposium on May 11, 2022",5/5/2022 1:00:00 PM
ARAV,Aravive Announces Poster Presentations at the 2022 ASCO Annual Meeting,4/29/2022 1:00:00 PM
ARAV,Cantor lists pharma stocks with notable changes in short interest,4/12/2022 7:25:18 PM
ARAV,Aravive Announces Closing of $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules,4/1/2022 1:00:00 PM
ARAV,Aravive Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates,3/31/2022 10:05:00 PM
ARAV,Aravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules,3/30/2022 2:00:00 PM
ARAV,"Aravive Appoints Scott Dove, Ph.D., as Chief Operating Officer",3/22/2022 12:00:00 PM
ARAV,Aravive to Participate In-Person at 34th Annual ROTH Conference,3/7/2022 1:00:00 PM
ARAV,Aravive Announces Positive Updated Data and New Biomarker Data from Phase 1b Study of Batiraxcept in Clear Cell Renal Cell Carcinoma,3/3/2022 1:00:00 PM
ARAV,Aravive to Present Updated Modeling Data from Batiraxcept Clinical Trials at the AACR Annual Meeting,3/2/2022 1:00:00 PM
ARAV,Aravive begins dosing in phase 2 study of batiraxcept to treat kidney cancer,1/31/2022 2:19:36 PM
ARAV,"Pre-market Movers: MYNZ, WEJO, ANNX, ARAV, SENS… ",1/5/2022 1:32:41 PM
ARAV,34 Stocks Moving In Tuesday's Mid-Day Session,1/4/2022 6:01:06 PM
ARAV,58 Biggest Movers From Friday,12/6/2021 10:33:07 AM
ARAV,Aravive to Participate in Fireside Chat at Piper Sandler 33rd Annual Virtual Healthcare Conference,11/15/2021 1:00:00 PM
ARAV,Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma,11/12/2021 1:00:00 PM
ARAV,Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma to be Presented at 2021 Society...,11/9/2021 2:00:00 PM
ARAV,Aravive Reports Third Quarter 2021 Financial Results and Provides Corporate Updates,10/28/2021 10:01:00 PM
ARAV,"The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results",10/7/2021 2:23:53 PM
ARAV,"The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal",10/6/2021 1:33:33 PM
ARAV,"The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout",10/5/2021 2:01:45 PM
ARAV,Aravive to Present New Preliminary Data from Phase 1b Trial Evaluating AVB-500 in Clear Cell Renal Cell Carcinoma at 2021 Society for Immunotherapy of Cancer Annual Meeting,10/1/2021 2:00:00 PM
ARAV,Aravive to Participate in Fireside Chat at Cantor Fitzgerald Virtual Global Healthcare Conference,9/16/2021 1:00:00 PM
ARAV,Aravive to Participate in Fireside Chat at H.C. Wainwright 23rd Annual Global Investment Conference,9/1/2021 1:00:00 PM
ARAV,"The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data",8/20/2021 1:45:43 PM
ARAV,"The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline",8/18/2021 1:37:56 PM
ARAV,"The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business",8/17/2021 2:28:53 PM
ARAV,Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma,8/9/2021 1:00:00 PM
ARAV,Aravive Reports Second Quarter 2021 Financial Results and Provides Corporate Updates,8/5/2021 1:00:00 PM
ARAV,Aravive to Participate in Fireside Chat at 2021 BTIG Biotechnology Conference,7/27/2021 1:00:00 PM
ARAV,Aravive Achieves Second Development Milestone from 3D Medicines,7/15/2021 1:00:00 PM
ARAV,Aravive to Participate in Fireside Chat at 2021 William Blair Biotech Focus Conference,7/7/2021 1:00:00 PM
ARAV,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday,6/25/2021 11:24:13 AM
ARAV,36 Stocks Moving In Thursday's Mid-Day Session,6/24/2021 6:10:26 PM
ARAV,Aravive Announces Three New Appointments to its Board of Directors,5/18/2021 1:00:00 PM
ARAV,Aravive Reports First Quarter 2021 Financial Results and Announces Plans to Investigate  AVB-500 in Clinical Trial as First-Line Treatment for Pancreatic Cancer,5/6/2021 1:00:00 PM
ARAV,52 Biggest Movers From Yesterday,4/28/2021 11:11:53 AM
ARAV,38 Stocks Moving In Tuesday's Mid-Day Session,4/27/2021 6:01:29 PM
ARAV,58 Biggest Movers From Yesterday,3/23/2021 10:16:23 AM
ARAV,35 Stocks Moving In Monday's Mid-Day Session,3/22/2021 5:04:04 PM
ARAV,"Clovis Oncology, Marker Therapeutics leads healthcare gainers; Idera Pharmaceuticals, Praxis Precision Medicines among major losers",3/19/2021 3:04:17 PM
ARAV,"Aravive shares rise on Q4 results, pipeline updates",3/16/2021 2:18:25 PM
ARAV,"Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca's Anemia Drug, Earnings and Presentations",3/14/2021 1:14:58 PM
ARAV,Aravive to Present Phase 1b Data Evaluating AVB-500 in Platinum Resistant Ovarian Cancer at 2021 Society of Gynecologic Oncology Annual Meeting,3/12/2021 1:00:00 PM
ARAV,"Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2021",3/8/2021 4:04:40 PM
ARAV,Aravive to Participate in Upcoming Virtual Investor Conferences in March,3/2/2021 1:00:00 PM
ARAV,"Aravive Announces $21.0 Million Registered Direct Offering with Eshelman Ventures, LLC Priced At-The-Market",2/16/2021 1:00:00 PM
ARAV,Aravive to Present at the H.C. Wainwright Virtual BioConnect Conference,1/4/2021 10:05:00 PM
ARAV,Aravive Announces Board Member Transition to Advisory Role,1/1/2021 1:00:00 AM
ARAV,Aravive late-stage study of AVB-500 in platinum-resistant ovarian cancer part of FDA's innovative trial design initiative,11/19/2020 1:57:16 PM
ARAV,Aravive to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference,11/16/2020 10:05:00 PM
ARAV,"Aravive to Host Virtual Expert Event Focused on Ovarian and Renal Cancer on November 20, 2020",11/10/2020 10:05:00 PM
ARAV,Aravive Reports Third Quarter 2020 Financial Results and Provides Corporate Updates,11/5/2020 10:05:00 PM
ARAV,Aravive Appoints Michael W. Rogers to Board of Directors,9/17/2020 1:00:10 PM
ARAV,"Aravive Appoints Reshma Rangwala, M.D., Ph.D., as Chief Medical Officer",9/15/2020 1:00:10 PM
ARAV,Aravive to Participate in Upcoming Virtual Investor Conferences in September,9/8/2020 1:00:10 PM
ARAV,Aravive Strengthens Leadership Team with Appointment of Key Industry Veterans,8/27/2020 1:00:10 PM
ARAV,Aravive Reports Second Quarter 2020 Financial Results and Provides Recent Corporate Updates,8/3/2020 10:01:10 PM
ARAV,Aravive to Participate in Upcoming Virtual Investor Conferences in August,7/30/2020 1:00:10 PM
ARAV,Aravive Announces Successful Completion of Phase 1b Trial Evaluating AVB-500 in Platinum Resistant Ovarian Cancer,7/23/2020 1:00:10 PM
ARAV,Aravive Added to the Russell 2000® and Russell 3000® Indexes,6/30/2020 10:05:10 PM
ARAV,Aravive To Present at The 2020 RBC Capital Markets Global Healthcare Conference,5/12/2020 2:00:10 PM
ARAV,Aravive Reports First Quarter 2020 Financial Results and Provides Recent Corporate Updates,5/6/2020 10:05:10 PM
ARAV,Aravive and WuXi Biologics Form Strategic Collaboration to Develop Novel High-Affinity Bispecific Antibodies Targeting Cancer and Fibrosis Using the WuXiBody™ Platform,4/30/2020 2:00:10 PM
ARAV,Aravive Announces Board Composition and Executive Management Transitions,4/9/2020 1:08:32 PM
ARAV,Aravive Announces AVB-500 Improves Anti-Tumor Effects when Combined with Anti-Angiogenic Bevacizumab or PARP Inhibitor Olaparib in Preclinical Models of Uterine Cancer,3/30/2020 2:00:00 PM
ARAV,"Aravive Reports Fourth Quarter and Twelve Months Ended December 31, 2019 Financial Results and Provides Recent Corporate Updates",3/27/2020 1:00:00 PM
ARAV,Aravive Announces Initiation of Investigator-Sponsored Phase 1/2 Study of AVB-500 in Combination with Avelumab in Patients with Advanced Urothelial Carcinoma (COAXIN),3/24/2020 1:00:00 PM
ARAV,Aravive To Present at The Cowen and Company 40th Annual Health Care Conference,2/25/2020 10:07:34 PM
ARAV,Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial,2/18/2020 2:00:00 PM
ARAV,Aravive Receives IND Clearance for Phase 1b/Phase 2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma,1/13/2020 2:00:00 PM
ARAV,Aravive Announces Management Changes,1/9/2020 10:05:00 PM
ARAV,Aravive Initiates a Phase 2a Clinical Trial of AVB-500 in Patients with Kidney Fibrosis,12/20/2019 2:00:00 PM
ARAV,Aravive Announces Participation at the 2019 Piper Jaffray Healthcare Conference,12/2/2019 2:00:00 PM
ARAV,Aravive Announces Pricing of Public Offering of Common Stock,11/27/2019 2:30:10 PM
ARAV,Aravive Announces Proposed Public Offering of Common Stock,11/26/2019 11:14:16 PM
ARAV,"Aravive Reports Positive Data Supporting Relationship Between AVB-500 Levels, Anti-Tumor Activity and Progression Free Survival in Women with Ovarian Cancer",11/20/2019 1:00:00 PM
ARAV,Aravive and AstraZeneca Announce Initiation of Randomized Phase 1/2 Study of AVB-500 in Combination with Durvalumab in Patients with Platinum-Resistant Recurrent Epithelial Ovarian Cancer,11/12/2019 2:00:00 PM
ARAV,CORRECTION – Aravive Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Updates,11/8/2019 7:11:08 PM
ARAV,Aravive Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Updates,11/7/2019 10:05:00 PM
ARAV,Aravive Announces Publication of AVB-500 Nonclinical Study in Treatment-Resistant ccRCC Animal Models in Cancer Research,10/18/2019 2:00:05 PM
ARAV,Aravive Presents Positive Data from Initial 12 Patients in Phase 1b Portion of its Phase 1b/2 Ovarian Cancer Study of AVB-500 in Late Breaking Oral Presentation at European Society for Medical...,9/27/2019 4:15:00 PM
ARAV,"Week Ahead In Pharma: 9 Stocks To Watch (AVXL, GMAB, ARAV…) ",9/21/2019 1:03:07 PM
ARAV,"6 Top Gainers In Healthcare Sector (AIM, EDSA, ARAV…) ",9/20/2019 3:39:05 AM
ARAV,"5 Top Gainers In Healthcare Sector (LXRX, ECOR, ARAV…) ",9/19/2019 4:38:56 AM
ARAV,Aravive to Present Late-Breaking Oral Presentation at European Society for Medical Oncology Congress 2019 in Barcelona,9/18/2019 2:00:00 PM
ARAV,Aravive Announces Executive Management Transition Plan,8/8/2019 10:15:00 PM
ARAV,Aravive Reports Second Quarter 2019 Financial Results and Provides Recent Corporate Updates,8/7/2019 10:05:00 PM
ARAV,"5 Top Gainers In Healthcare Sector (ARAV, NBSE, SESN…) ",8/1/2019 3:07:34 AM
ARAV,Aravive Reports Preliminary Results of AVB-500 from the First Cohort of the Phase 1b/Phase 2 Recurrent Platinum Resistant Ovarian Cancer Trial ,7/31/2019 1:05:00 PM
ARAV,Aravive Announces Independent Data Monitoring Committee Recommends Continuation of Phase Ib Study of AVB-500 In Recurrent Platinum Resistant Ovarian Cancer After Review of First Two Cohorts of...,7/8/2019 1:05:00 PM
ARAV,Aravive Reports First Quarter 2019 Financial Results and Provides Recent Corporate Updates,5/8/2019 10:05:00 PM
ARAV,"7 Top Gainers In Pharma Sector (ATHE, NSPR, NCNA…) ",4/30/2019 3:23:10 AM
ARAV,Aravive Announces Retrospective Analysis Showing Increased GAS6 Levels Associated with Chemoresistance and Decreased Progression Free Survival in Ovarian Cancer,3/19/2019 12:05:00 PM
ARAV,CORRECTING AND REPLACING - Aravive Announces Participation at Cowen and Company 39th Annual Health Care Conference,3/8/2019 10:05:00 PM
ARAV,Aravive Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Recent Corporate Updates,3/7/2019 10:04:00 PM
ARAV,Aravive Announces Participation at Cowen and Company 39th Annual Health Care Conference,3/5/2019 10:05:00 PM
ARAV,"Aravive to Report Fourth Quarter and Full Year 2018 Financial Results and Corporate Updates on March 7, 2019",2/28/2019 10:10:00 PM
ARAV,Aravive Receives Additional $2.6 Million Disbursement from the Cancer Prevention and Research Institute of Texas,2/19/2019 1:00:00 PM
ARAV,"Aravive Expands Executive Team with Promotion of Gail McIntyre, PhD, DABT to Chief Scientific Officer",2/14/2019 1:00:00 PM
ARAV,"Aravive to Host Key Opinion Leader Breakfast Symposium on AVB-S6-500 and the GAS6-AXL Pathway on February 5, 2019",1/29/2019 1:00:00 PM
ARAV,Aravive Biologics Initiates Phase 1b Portion of Phase 1b/2 Clinical Trial of AVB-S6-500 in Platinum-Resistant Recurrent Ovarian Cancer,12/11/2018 2:05:00 PM
ARAV,Aravive Announces Participation at Upcoming Investor Conference,11/26/2018 1:00:00 PM
ARAV,Aravive Presents Detailed Results of Phase 1 Clinical Trial of AVB-S6-500 at the 2018 EORTC-NCI-AACR Symposium,11/13/2018 1:00:00 PM
ARAV,Aravive Reports Third Quarter 2018 Financial Results and Provides Company Updates,11/6/2018 10:05:00 PM
